IDEAYA Biosciences and Servier report data from three ESMO 2026 clinical trials
The companies say the data support the potential of darovasertib as a therapy for uveal melanoma. The alert provides no trial results or further details.
The companies say the data support the potential of darovasertib as a therapy for uveal melanoma. The alert provides no trial results or further details.